PMID: 9435872Jan 22, 1998Paper

Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer

Cancer Immunology, Immunotherapy : CII
Peter KuferGert Riethmuller

Abstract

Unlike monoclonal antibodies, clinical application of bispecific antibodies has so far lagged behind because of difficult, low-yield production techniques as well as considerable toxicity attributed to bispecific antibody preparations containing immunoglobulin-Fc parts and anti-CD3 homodimers. These difficulties were overcome by recombinant generation of a bispecific single-chain antibody (bscAb) joining two single-chain Fv fragments via a five-amino-acid glycine-serine linker. The anti-CD3 specificity directed against human T cells was combined with another specificity against the epithelial 17-1A antigen. The following domain arrangement was critical in this individual case to obtain a fully functional bscAb: VL17-1A-VH17-1A-VHCD3-VLCD3. The bscAb was expressed in chinese hamster ovary cells with a yield of 15 mg/l culture supernatant whereas numerous attempts to obtain a functional protein expression in Escherichia coli failed. The low-molecular-mass bispecific construct (60 kDa) could easily be purified by its C-terminal histidine tail. The antigen-binding properties are indistinguishable from those of the corresponding univalent single-chain Fv fragments as shown by enzyme immunoassay and flow cytometry. We could show that...Continue Reading

Citations

Aug 28, 1998·Current Opinion in Biotechnology·P J Hudson
May 31, 2007·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Zhang-Min YangLu-Sheng Si
Nov 24, 2004·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Masahide KurokiTetsushi Kinugasa
Apr 1, 2011·Expert Opinion on Biological Therapy·Bryan D ChoiJohn H Sampson
Feb 3, 2005·International Journal of Cancer. Journal International Du Cancer·Patrick HoffmannPatrick A Baeuerle
Aug 28, 2009·Pharmazie in unserer Zeit·Helma FreitagT Dingermann
Apr 28, 2004·Trends in Biotechnology·Peter KuferPatrick A Baeuerle
Jun 27, 2015·Seminars in Hematology·Felix S LichteneggerMarion Subklewe
Oct 11, 2005·Drug Discovery Today·Evelyn WolfPatrick A Baeuerle
Nov 5, 2014·Immunology and Cell Biology·Amelia M HuehlsCharles L Sentman
Jun 19, 2001·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·R RiesenbergH Lindhofer
Jan 11, 2017·MAbs·Ulrich Brinkmann, Roland E Kontermann
Apr 19, 2002·Cancer Gene Therapy·Stephane PaulR Bruce Acres
Aug 15, 2020·Frontiers in Oncology·Wen-Qi CaiHong-Wu Xin
Jun 9, 2020·Cancer Metastasis Reviews·Olivier GiresPatrick A Baeuerle
Feb 14, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tobias SpeckChristine E Engeland
Dec 29, 2020·Bioorganic & Medicinal Chemistry·Jisoo ParkTae Hyeon Yoo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.